Who we are

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems dedicated to making genomics useful for all. Innovating at the intersection of technology, biology, and health, we are reimagining what's possible for human health and the health of our planet, including how diseases—from cancer to COVID-19—are discovered, detected, diagnosed, and treated. We provide sequencing innovations that are enabling researchers and clinicians to usher in the future of personalized medicine.

Fast facts

<table>
<thead>
<tr>
<th>Founded in</th>
<th>Number of employees</th>
<th>Core annual revenue (2023)</th>
<th>Net sequencing installed base</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>~9,250</td>
<td>$4.43B USD</td>
<td>&gt; 21,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Headquarters</th>
<th>Countries served</th>
<th>Chief Executive Officer</th>
</tr>
</thead>
<tbody>
<tr>
<td>San Diego, California, USA</td>
<td>&gt; 160</td>
<td>Jacob Thaysen</td>
</tr>
</tbody>
</table>

Sequencing systems

Next-generation sequencing (NGS) is revolutionizing research, enabling experiments that weren’t possible before. Illumina offers a range of innovative NGS platforms that deliver exceptional data quality and accuracy, at a massive scale.

Illumina Connected Software

Integrating seamlessly with our sequencing systems, Illumina Connected Software supports genomic and clinical researchers from primary through tertiary analysis and optimizes lab and sample management. It offers the most accurate and comprehensive variant calling with DRAGEN™ 4.2 secondary analysis,† powering greater applications and discovery. Balancing approachability with customization, Illumina Connected Software enables insights for single-sample or population-wide studies.

For Research Use Only. Not for use in diagnostic procedures.
*For In Vitro Diagnostic Use. Not available in all regions and countries.
† As compared against all participating solutions’ F1 score using PrecisionFDA v2 Truth Challenge Benchmark Data; Illumina internal data on file for DRAGEN v4.2 software, data not from Illumina provided by Precision FDA v2 Truth Challenge 2020.
Since 2001, the cost of DNA sequencing has dropped more than 100,000x from $100 million USD per human genome to $200 USD list price.

Where we operate

- **United States**
  - San Diego (headquarters)
  - Foster City
  - Hayward
  - Baltimore
  - Madison
- **Australia**
  - Melbourne
- **Austria**
  - Vienna
- **Belgium**
  - Brussels
  - Mechelen
- **Brazil**
  - São Paulo
- **China**
  - Beijing
  - Shanghai
  - Guangzhou
  - Hangzhou
  - Nanjing
  - Taipei City
- **India**
  - Bengaluru
- **Italy**
  - Milan
  - Tel Aviv
- **Japan**
  - Tokyo
  - Osaka
- **Netherlands**
  - Eindhoven
- **Singapore**
- **South Korea**
  - Seoul
- **Turkey**
  - Istanbul
- **United Arab Emirates**
  - Dubai
- **United Kingdom**
  - Cambridge

Creating positive impact

By embedding our corporate social responsibility (CSR) strategy into business, we are driving positive stakeholder impact and long-term shareholder value.

Our recognition

- 3BL 100 Best Corporate Citizens
- AmCham Corporate and Societal Action: Recognition for Excellence in Singapore (CARES)
- America’s Most JUST Companies by JUST Capital and CNBC
- Disability Equality Index, Best Places to Work for Disability Inclusion
- Dow Jones Sustainability Indices
- Fast Company’s Innovation by Design Awards for the NovaSeq X Series (honoree)
- Fast Company’s World Changing Ideas Awards for the NovaSeq X Series (honoree)
- Forbes America’s Best-in-State Employers
- Forbes World’s Best Employers
- Forbes World’s Top Companies for Women
- IBO Gold Award for Design for the NovaSeq X Series
- Military Times Best for Vets
- Newsweek America’s Greatest Workplaces for Diversity
- Newsweek America’s Most Responsible Companies
- TIME World’s Best Companies
- U.S. News & World Report Best Companies to Work For